Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan

Completed

• Conditions: Eyelash Hypotrichosis
• Interventions: Drug: Bimatoprost cutaneous solution 0.03%

• Registration Number: NCT02505776
• Lead Sponsor: Allergan

Brief Summary

This is a post-marketing surveillance study in Japan that will evaluate the safety and patient satisfaction with GLASH VISTA™ (bimatoprost cutaneous solution 0.03%) in the treatment of hypotrichosis of the eyelashes.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-12-08
• Study First Submitted: 2015-07-21
• Study First Submitted QC: 2015-07-21
• Study First Posted: 2015-07-22
• Primary Completion: 2018-05-21
• Study Completion: 2018-05-21
• Status Verified: 2018-08
• Last Update Submitted: 2018-08-13
• Last Update Posted: 2018-08-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1699

Inclusion Criteria

-Patients who have been prescribed GLASH VISTA™ in clinical settings and filled at least one prescription for GLASH VISTA™.

Exclusion Criteria

-None.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
GLASH VISTA™	Bimatoprost cutaneous solution 0.03%	Patients with eyelash hypotrichosis prescribed bimatoprost cutaneous solution 0.03% (GLASH VISTA™) as per local standard of care in clinical practice.

Primary Outcome Measures

Name	Time	Method
Change from Baseline in Patient Satisfaction with Eyelashes As Measured by the 3-Item Patient Eyelash Satisfaction Survey	Baseline, Month 12
Number of Participants With Adverse Events	Up to 12 Months